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ABSTRACT 
Simvastatin (SV) is marketed as a lactone ester prodrug which is hydrolyzed to the active simvastatin 
hydroxyacid (SVA). SV is characterized by a low solubility and undergoes extensive first-pass 
metabolism. In this study, the influence of the upper gastrointestinal environment on the 
intraluminal behavior of simvastatin was investigated by a series of in vitro experiments. Dissolution, 
stability and two-stage dissolution tests were performed using simulated and human gastrointestinal 
fluids.  
The dissolution studies revealed a relatively slow dissolution of SV as well as conversion of SV to SVA. 
The hydrolysis of SV was further examined and stability studies indicated a faster conversion in 
gastric fluids than in intestinal fluids. These isolated phenomena were then confirmed by the more 
integrative two-stage dissolution studies.  
To estimate the predictive value of the in vitro tests, an additional in vivo study was performed in 
which the gastrointestinal concentration-time profiles also revealed a slow dissolution of SV and 
faster degradation of SV to SVA in the stomach than in the intestinal tract. However, the plasma 
concentrations of SV and SVA did not directly correlate with the observed gastrointestinal 
concentrations, suggesting that gut wall and hepatic metabolism have a greater impact on systemic 
exposure of SV than the intraluminal interconversion between SV and SVA.  
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1. INTRODUCTION 
Nowadays, most drug candidates suffer from low aqueous solubility or low intestinal permeability, 
resulting in poor oral bioavailability. (Lipinski et al., 2001) The development of prodrugs exhibiting 
improved solubility and/or permeability has been successful as a strategy to counter these 
challenges. (Jarkko et al., 2008) It has been demonstrated, however, that premature intraluminal 
hydrolysis mediated by hydrolyzing enzymes present in the intestinal fluids may significantly alter the 
intestinal absorption of a prodrug. (Brouwers et al., 2007); (Stappaerts et al., 2015) It has for instance 
been shown that intraluminal degradation of the ester prodrug tenofovir disoproxil fumarate takes 
place in vivo, illustrating that the esterases present in the intestinal fluids may undermine the 
intended enhanced permeability. In another recently described study, the hydrolyzing capacity of 
intestinal fluids was revealed to be an effective trigger causing abiraterone supersaturation upon 
administration of the ester prodrug abiraterone acetate; esterase-mediated hydrolysis was shown to 
be beneficial for the intestinal absorption of abiraterone. (Stappaerts et al., 2015) It is clear that the 
intraluminal behavior of ester prodrugs can be diverse and may have significant repercussions on 
intestinal drug absorption. In vitro stability testing in biorelevant media containing hydrolyzing 
enzymes is clearly an important step in assessing the feasibility of a prodrug approach.  
Statins are indispensable in the primary and secondary prevention of cardiovascular diseases 
worldwide. (Scandinavian Simvastatin Survival Study Group, 1994) This class of drugs competitively 
inhibits the rate-limiting step of cholesterol biosynthesis, mediated by 3-hydroxy-3-methylglutaryl-
coenzym A reductase, decreasing cholesterol neogenesis. (Vickers et al., 1990b) Statins are on the 
market as either the active hydroxyacid form (atorvastatin, fluvastatin, rosuvastatin and pravastatin) 
or as lactone (a cyclic ester) prodrug (simvastatin (SV) and lovastatin). (Li et al., 2011); (Lennernäs 
and Fager, 1997) SV is hydrolyzed to the active metabolite simvastatin hydroxyacid (SVA) by 
esterases, paraoxonases and by non-enzymatic hydrolysis (Figure 1). (Pedersen and Tobert, 
2004)(Prueksaritanont, 2002) 
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Simvastatin has a low oral bioavailability of less than 5%, which may be attributed to low intestinal 
uptake and extensive first-pass metabolism. (Kato, 2008) Solubilized simvastatin, on the other hand, 
is well absorbed from the gastrointestinal tract. (Mauro, 1993) This was confirmed by a high apical to 
basolateral transport across Caco-2 cell layers for both SV and SVA. (Li et al., 2011) Hepatic uptake of 
SV occurs through a combination of passive and active transport mediated by the liver-specific 
isoforms of the Organic Anion Transporting Polypeptide (OATP) family, i.e. OATP 1B1/1B3. 
(Thompson et al., 2013) In the liver, SV is metabolized via various pathways including acid/lactone 
interconversion. Both SV and SVA are substrates for CYP3A4. (Figure 1) (Vickers et al., 1990b); 
(Pedersen and Tobert, 2004); (Prueksaritanont, 2002); (Bottorff and Hansten, 2000); (Cheng et al., 
1994) Biliary excretion is found to be the major route of elimination of the SV metabolites. (Vickers et 
al., 1990a) 
In view of our recent findings on the intraluminal stability of several ester prodrugs, the aim of this 
study was to gain more insight into the intraluminal behavior of the cyclic ester SV. To reach this 
goal, several in vitro experiments were designed involving the use of biorelevant media such as 
simulated and human gastric and intestinal fluids. In addition, more complex in vitro models were 
used including two compartmental set-ups to further increase the in vivo similarity. In addition, a 
clinical study was performed to investigate (1) for the first time the in vivo intraluminal behavior of 
SV and (2) the predictive value of the performed in vitro tests. 
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2. MATERIALS AND METHODS 
2.1. Chemicals 
Simvastatin (SV) and simvastatin acid (SVA) were both obtained from Sigma-Aldrich (St. Louis, MO) as 
well as rosuvastatin (RSV), monobasic potassium phosphate monohydrate (KH2PO4.H2O), bis-4-
nitrophenylphosphate and pancreatin from porcine pancreas (powder, suitable for cell culture, 4x 
USP specifications). Dimethylsulfoxide (DMSO) and tetrabutylammonium sulfate were obtained from 
Acros-Organics (Geel, Belgium). Acetic acid was purchased from Chem-lab (Zedelgem, Belgium). 
Acetonitrile was purchased from Fisher Scientific (Leicestershire, UK). Simulated intestinal fluid (SIF) 
powder was purchased from Biorelevant (Croydon, UK). Methanol and sodium acetate trihydrate 
were purchased from VWR International (Leuven, Belgium). Water was purified with a Maxima 
system (Elga Ltd., High Wycombe Bucks, UK). For the measurements of the pH, a Portamess 911 pH-
meter (Knick GmbH & Company, Berlin, Germany) was used. All stock solutions were prepared in 
DMSO. 
2.2. Stabilization mixture  
Precautions were taken to guarantee stability of the samples before the analysis. It is known that the 
stability of simvastatin decreases with increasing temperature whereas sufficient stability has been 
reported in a pH range of 3 to 6. (Álvarez-Lueje et al., 2005); (Di and Kerns, 2009) All samples were 
immediately diluted 1/100 in a stabilization mixture (pH 3.5), consisting of MeOH:0.02N HCl (50:50) 
containing 400 µM of the esterase inhibitor bis-4-nitrophenylphosphate. The stability of the ester 
prodrug was confirmed in this stabilization mixture.  
2.3. Media 
Fasted state simulated intestinal fluid (FaSSIF) and fasted state simulated gastric fluid (FaSSGF) were 
made according to the manufacturer’s preparation protocol (Biorelevant®, Croydon, UK). FaSSIF was 
prepared by dissolving SIF powder (2.24 mg/mL) in a phosphate buffer (pH 6.5). To provide the 
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simulated fluids with hydrolyzing capacity, FaSSIF was supplemented with pancreatin (10 mg/mL) as 
described by Borde et al. (Borde et al., 2012) After vortex mixing, this suspension was centrifuged 
(2.880 g) and the supernatant was used for the stability study. FaSSGF was prepared by dissolving SIF 
powder (0.06 mg/mL) in an HCl/NaCl solution (pH 1.6). For the two-stage dissolution experiment 
double concentrated FaSSIF (pH 7.5) was prepared in order to obtain taurocholate and lecithin 
concentrations of 3 mM and and 0.75 mM, respectively, and a pH of 6.5 upon 1:1 dilution with 
FaSSGF. 
Fasted state human gastric (FaHGF) and intestinal (FaHIF) fluids were aspirated from four healthy 
volunteers (two males, two females) aged between 23 and 27 years. The study was approved by the 
Committee of Medical Ethics of the University Hospitals Leuven (S53791), Belgium and the procedure 
followed the tenets of the Declaration of Helsinki. HIF were collected from the duodenum (D2–D3) 
with a double-lumen polyvinyl catheter [Salem Sump Tube 14 Ch (external diameter 4.7 mm), 
Sherwood Medical, Petit Rechain, Belgium]. Samples were collected every 10 min for 120 min and 
kept on ice until pooling. Pooled samples were made by combining equal volumes of the aspirates 
from all four volunteers. Pooled HIF were stored at −30°C until further use. A similar approach was 
used for the collection of human gastric fluids (HGF) in which a double-lumen polyvinyl catheter was 
positioned in the stomach. The pH of the pooled gastric and intestinal fluids of the fasted state 
amounted to 1.8 and 6.84, respectively. 
2.4. In silico profiling  
MarvinSketch (ChemAxon, Budapest, Hungary) was used to determine key physicochemical 
properties including dissociation constant (pKa) and aqueous solubility. 
2.5. In vitro studies 
2.5.1. Dissolution study 
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The dissolution behavior of SV and SVA in gastric fluids, FaHGF (pH 1.72) and FaSSGF (pH 1.6), was 
determined by adding 0.13 mg to 1 mL of FaSSGF. An amount of 0.13 mg reflects the intake of 1 
tablet of 40 mg together with 250 mL water, further diluted in 50 mL of residual stomach fluids. The 
experiments were performed in Eppendorf tubes that were shaken horizontally (175 rpm) at 37 °C 
for 2 h. Samples were taken at predetermined time points: 5, 15, 30, 60, 90 and 120 min.  
The dissolution behavior of SV and SVA in FaHIF and FaSSIF was determined by adding 1 mg of SV or 
SVA to 1 mL of each medium. The experiments were performed in Eppendorf tubes that were shaken 
horizontally (175 rpm) at 37 °C for 4 h. Samples were taken at predetermined time points: 10, 20, 40, 
60, 120, 180 and 240 min.  
To determine the concentrations of SV and SVA, the samples were centrifuged (10 min, 20.817 g) and 
the supernatant was diluted 1/100 in the stabilization mixture before analysis. To determine the total 
amount per volume of SV and SVA, the samples were immediately diluted 1/100 in the stabilization 
mixture, followed by a centrifugation step (10 min, 20.817 g). The supernatant was used for analysis. 
All experiments were performed in triplicate. 
2.5.2. Stability study  
To explore the stability of SV and SVA in gastric fluids, 10 µM of SV and SVA was spiked into 
simulated and human gastric fluids: FaSSGF and FaHGF. Samples were taken at predetermined time 
points: 0, 60, 90 and 120 min. In addition to the gastric fluids, the stability of SV and SVA was also 
studied in simulated and human intestinal fluids. Three different media with increasing levels of 
complexity in the following order: FaSSIF, FaSSIF supplemented with pancreatin (10 mg/mL) and 
FaHIF. Similar to the gastric fluids, 10 µM of SV or SVA was spiked into the different media. Samples 
were taken at predetermined time points: 0, 60, 120, 180 and 240 min. All samples were diluted 
immediately 1/100 in the stabilization mixture. The samples were centrifuged (20.817 g) and the 
supernatant was used for analysis. All experiments were performed in triplicate.  
2.5.3. Two-stage dissolution testing 
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Two-stage dissolution tests were performed using simulated and human gastric and intestinal fluids. 
For the simulated fluids, one tablet of Zocor® (simvastatin, 40 mg) was added to 50 mL of FaSSGF 
maintained at 37°C and stirred at 400 rpm for 15 min. The volume was taken down to 50 mL to 
prevent excessive usage of the simulated fluids. Samples were taken every 5 min. After 15 min, the 
FaSSGF solution was transferred to 50 mL of double concentrated FaSSIF maintained at 37°C and 
stirred at 400 rpm. Samples were taken at predetermined time points (30, 60, 90 and 120 min). The 
pH of FaSSIF upon dilution amounted to 6.5.  
Since human intestinal and gastric fluids are scarce and relatively difficult to obtain in comparison to 
the more readily available simulated fluids, the volumes were reduced for the experiments involving 
human media. Instead of adding a tablet of Zocor® to a volume of 50 mL, 0.8 mg of SV powder was 
added to 1 mL of FaHGF maintained at 37°C and stirred at 400 rpm. The addition of 0.8 mg to 1 mL is 
equivalent to the approach that was used for the simulated fluids, where one tablet of 40 mg 
simvastatin was added to 50 mL of FaSSGF. Similar proportions were used in both conditions to be 
able to compare the obtained results. After 15 min, this solution was added to 1 mL of FaHIF 
maintained at 37°C and stirred at 400 rpm. Samples were taken at predetermined time points (60, 
90, 120, and 180 min). The pH of FaHIF decreased from 6.84 to 5.21 upon dilution. All samples were 
centrifuged (20.817 g) and the supernatant was diluted 1/100 in the stabilization mixture before 
analysis. All experiments were performed in triplicate.  
2.6. Clinical trial 
To be able to compare the in vitro observations to the in vivo situation, a clinical study was 
performed. This study included five healthy volunteers (two men, three women) aged between 22 
and 26 years. The procedure followed the tenets of the Declaration of Helsinki and was approved by 
the Committee of Medical Ethics of the University Hospitals Leuven, Belgium (S55581). All volunteers 
provided written informed consent to participate in this study. After an overnight fast (12 h), two 
double-lumen polyvinyl catheters [Salem Sump Tube 14 Ch (external diameter 4.7 mm), Sherwood 
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Medical, Petit Rechain, Belgium] were introduced via the nose and positioned into the stomach and 
the duodenum (D2/D3). The position of both catheters was checked by fluoroscopy. It has previously 
been reported that the presence of a transpyloric tube does not influence gastric emptying or 
duodenogastric reflux. (Müller-Lissner et al., 1982) A single tablet of Zocor® (simvastatin, 40 mg) was 
administered together with 250 mL of water. Volunteers were asked to sit in upright position in a bed 
during the sampling procedure. Samples of human gastric and intestinal fluids (sample volume 
between 1.5 and 4 mL) were aspirated every 10 min for the first hour followed by samples every 15 
min up to 4 h. In parallel to the sampling of gastrointestinal fluids, venous blood samples were 
collected in heparinized tubes (BD Vacutainer systems, Plymouth, UK) at 0, 20, 40, 60, 80, 100, 120, 
160, 180, 210, 240, 300, 360, 420 and 480 min after drug intake. These blood samples were 
centrifuged at 2.880 g for 10 min at 4°C to obtain plasma samples which were stored at -30°C until 
further analysis. In the gastric and intestinal samples, both total amount per volume and the 
concentration of SV and SVA were measured. For the determination of the total amount per volume, 
10 µL of the aspirated fluids was directly diluted 1/100 in stabilization mixture. For the determination 
of the concentration, the samples were centrifuged (20.817 g, 5 min, 37°C) and the supernatant was 
diluted 1/100 in the stabilization mixture. All samples were stored at -30°C until further analysis. 
2.7. Analytical methods 
For the quantification of SV and SVA, an LC method with MS/MS detection was developed. All 
samples contained rosuvastatin as an internal standard at a final concentration of 200 nM. The 
detection of the 3 compounds was performed using a TSQ Quantum with electron spray ionization. 
The collision energy for simvastatin, simvastatin acid and rosuvastatin was 27, 33 and 17 V, 
respectively. Mass transitions for simvastatin, simvastatin acid and rosuvastatin were 441.2/325.1, 
435.1/319.1 and 480.2/268.0, respectively. The mass spectrometer was operated in the positive 
electrospray mode for SV and in the negative electrospray mode for both SVA and RSV. Both 
compounds SV and SVA were detected using two different instrument methods to avoid overlap in 
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the electrospray mode. For both methods, the spray voltage, capillary voltage and capillary 
temperature were 4.50 V, 12 V and 300°C, respectively. Nitrogen was used as the sheath gas (30 
arbitrary units), ion sweep (30 arbitrary units) and auxiliary gas (50 arbitrary units). Argon was used 
as the collision gas at a pressure of 1.5 mTorr. The following gradient of ACN/H2O/ammonium 
acetate buffer (pH 4.5) was run over a Kinetex C18 column (50 × 3 mm, 1.7 μm; Phenomenex) 
protected by a Krudkatcher Ultra HPLC In-Line filter (Phenomenex) at a flow rate of 300 μL/min: 
20/72/8 (0–2 min), changed linearly to 95/4/1 (2–2.51 min), keeping the 95/4/1 ratio constant for 1.5 
min after which it changed linearly back to the initial conditions of 20/72/8 over 2 min (4.01–6.0 
min). The injection volume was 10 μL and Xcalibur was used as the software program (Thermo-
Electron, San Jose, USA). 
Before quantification of simvastatin and simvastatin acid in plasma by LC-MS/MS, the compounds 
were extracted from the plasma samples. After diluting 400 µL of plasma in 400 µL of an ammonium 
acetate solution (100 mM, pH 4.5), 4 µL of internal standard solution in DMSO (RSV, 20 µM) was 
added. Yang et al. reported that the ammonium acetate buffer minimizes the interconversion 
between SV and SVA. (Yang et al., 2005) SV and SVA were extracted with 3 mL of diethyl-ether after 
10 min of rotatively shaking with a rotary mixer (Labinco 526). After extraction, the organic layer was 
transferred to a clean test tube and evaporated to dryness under a gentle stream of air. The residue 
was dissolved in 400 µL of a solution of water and methanol (50:50 v/v), of which 100 µL was injected 
in the LC-MS/MS system for the detection of each compound.  
The calibration curves were linear from 0.9 nM to 1 µM. Precision and accuracy errors determined at 
400 nM, 100 nM, 50 nM and 10 nM were below 10%. 
2.8. Pharmacokinetic parameters 
The pharmacokinetic parameters Cmax, Tmax, AUC0-8, AUC0-∞, Cl/F, MRT and Vdss were calculated using 
non-compartmental analysis. (Rosenbaum, 2011)  
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3. RESULTS AND DISCUSSION 
Studies discussing the behavior of ester containing compounds in human intestinal fluids have 
highlighted the impact of intraluminal hydrolysis on intestinal absorption. (Geboers et al., 2015); 
(Stappaerts et al., 2015) To gain more insight into the disposition of SV upon oral administration, 
several in vitro experiments reflecting gastrointestinal conditions were performed, including stability 
and dissolution experiments. The predictive value of these experiments was critically examined by 
comparing the outcomes of the in vitro studies with the results obtained from a comprehensive in 
vivo study, in which gastric, duodenal and plasma concentrations were determined.  
3.1. Dissolution study 
The results of the dissolution study of SV and SVA in both FaHGF and FaHIF are depicted in Figure 2A. 
After 2 h, the total amount per volume and the concentration of SV and SVA were determined. The 
‘total amount per volume’ refers to the solid and dissolved amount per volume of SV or SVA. 
‘Concentration’ refers to the dissolved amount of SV and SVA per volume. A total amount of 120 
µmol of SV per L was measured in FaSSIF and the SV concentration was 11 µM. Moreover, a 
significant conversion of SV to SVA was observed: since a total amount of 25 µmol of SVA per L was 
determined of which the solubilized concentration was 4 µM. These results suggest that SV partially 
degrades to SVA once dissolved in the gastric fluids. The fact that the solubility of SVA in the acidic 
gastric fluids is lower (pKa SVA = 4.21) than the solubility of SV, results in precipitation of a 
proportion of the formed SVA. 
In the pooled FaHIF (pH 6.84), the concentrations of SV and SVA upon dissolution of SV were 
measured over a period of 4 h (Figure 2B). The concentrations of SV and SVA that were reached after 
4 h of incubation amounted to 148±2 µM and 30±0.2 µM, respectively. This SV concentration is much 
higher than the solubility reported by Rao et al. in FaSSIF (40 µM). (Rao et al., 2010) This is probably 
due to the difference in composition of FaSSIF as compared to FaHIF. (Riethorst et al., 2015) Similar 
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to the gastric fluids, a conversion of SV to SVA was observed. Nevertheless, SV appeared to be more 
stable in the intestinal fluids than in the gastric fluids.  
3.2. Stability study 
The dissolution studies already indicated hydrolysis of SV in gastric and intestinal fluids. Since SV is a 
lactone prodrug, which has to be hydrolyzed in order to attain its active structure, it is important to 
investigate to which extent gastrointestinal fluids have an impact on the stability of SV. First, the 
stability of SV and SVA was explored in simulated and human gastric fluids of the fasted state. (Figure 
3A) Degradation profiles of SV in both simulated and human gastric fluids indicate that 50% of SV is 
converted to SVA after 90 min. This is in agreement with literature data which state that SV is 
unstable below pH 3. (Álvarez-Lueje et al., 2005) In a complementary experiment, the conversion in 
the opposite direction was also observed upon incubation of SVA in gastric media (data not shown). 
Considering the relatively low esterase activity in human gastric fluids and the fact that the simulated 
gastric fluids were not supplemented with hydrolyzing enzymes, the interconversion between SV and 
SVA is at least partly driven by the acidic pH. (Lund-Pero et al., 1994) 
In a next step, the stability of SV was explored in three different intestinal media with levels of 
complexity increasing in the following order: FaSSIF, FaSSIF supplemented with pancreatin and FaHIF. 
(Borde et al., 2012); (“U.S. Pharmacopeial Convention,” 2009) As compared to the gastric fluids, less 
degradation was observed (Figure 3B). The degradation of SV to SVA was strongest in FaHIF. As the 
pH of the simulated (pH = 6.5) and human (pH = 6.8) intestinal fluids was similar, the faster 
degradation in the more complex media confirms the contribution of enzymatic degradation. The 
stability of SVA was investigated in these different media as well. However, in contrast to the gastric 
fluids, the conversion of SVA to SV was negligible (data not shown). Prueksaritanont et al. stated 
that, in liver homogenates of humans, the hydrolytic rate of conversion of SV to SVA is more than 10-
fold higher than in the opposite direction. (Prueksaritanont et al., 2005) The current data suggest 
that this finding could also hold true in intestinal fluids.  
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Taking the results of both gastric and intestinal media into account, it can be suggested that the 
intestinal conversion of SV to SVA is mediated by an enzymatic pathway whereas the gastric 
conversion is mostly pH driven. Moreover, the conversion of SVA to the inactive lactone form SV was 
only observed in the gastric fluids and not in the intestinal fluids, suggesting that this reaction is also 
at least partly mediated by the low pH.  
3.3. Two-stage dissolution testing 
The in vitro experiments described so far, were designed to evaluate a number of individual 
physicochemical characteristics of SV, including dissolution, solubility and stability. To gain more 
insight into the overall gastrointestinal behavior upon oral administration of SV, a more integrated in 
vitro approach was designed, allowing the simultaneous assessment of dissolution, stability and 
gastrointestinal transfer effects. In this two-stage dissolution study, gastric and intestinal 
compartments are connected through a transfer step. Experiments were performed in simulated and 
human intestinal fluids.  
When simulated media were used, one tablet of Zocor® (simvastatin, 40 mg) was added to 50 mL of 
FaSSGF. The tablet completely disintegrated within 10 min and both SV and SVA were detected in the 
collected samples of the gastric compartment. After 15 min, the entire content of the vessel was 
transferred to 50 mL of double concentrated FaSSIF supplemented with double concentrated 
pancreatin (Figure 4A). The pH of the intestinal compartment upon transfer of the gastric fluids was 
6.5. The concentration of SV increased from 14.9 µM in the gastric compartment to 86.4 µM in the 
intestinal compartment. This is probably due to the solubility enhancing effect of the micelles 
present in the intestinal media. Data obtained from this two-stage dissolution study were in line with 
the dissolution and stability studies: (1) relatively slow, incomplete dissolution of SV reaching a 
concentration of 80 µM in the intestinal compartment after 2 h and (2) more extensive degradation 
of SV in the gastric fluids than in the intestinal fluids.  
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For the human media, 0.8 mg of simvastatin was added to 1 mL of FaHGF (pH 1.8). Again, in all 
gastric samples, both SV and SVA were observed, confirming the simultaneous dissolution and 
degradation of SV that was observed in the dissolution studies using FaHGF. After 15 min, the entire 
content was transferred to 1 mL of FaHIF (pH 6.84). Once SV was added to FaHIF, the concentration 
increased from 7.7 µM to 18 µM (Figure 4B). The increase in concentrations of SV upon transfer was 
also observed when using simulated intestinal fluids, confirming the solubility enhancing effect of the 
micelles present in the intestinal fluids. Similar to the two-stage dissolution testing in simulated 
fluids, hydrolysis of SV occurs faster in the gastric fluids than in the intestinal fluids. In the simulated 
fluids, concentrations of SV were higher than in the human fluids, both for gastric and intestinal 
media. This could be due to the presence of solubility or dissolution enhancing excipients in the 
tablet, such as hypromellose or hydroxypropyl cellulose. (Talukder et al., 2011) Francis et al. showed 
an increase in solubility of cyclosporine A when hypromellose was included in the formulation. 
(Francis et al., 2003) These excipients were not included in the two-stage dissolution studies using 
human intestinal media. 
3.4. Clinical study 
To date, no intraluminal in vivo data are available which characterize the intestinal behavior of SV. 
Therefore, a clinical study was performed in which gastric and intestinal fluids were aspirated and 
analyzed for the total amounts per volume and the concentrations of SV and SVA. In parallel, blood 
samples were collected to investigate the appearance of SV and SVA in the systemic circulation. A 
similar approach was already successfully applied to investigate the intestinal behavior of the ester 
prodrugs fosamprenavir and tenofovir disoproxil fumarate. (Brouwers et al., 2007); (Geboers et al., 
2015) 
3.4.1. Plasma concentration-time profiles 
Although our study mainly focused on the intestinal behavior of SV, blood sampling allows validating 
our results in view of earlier performed clinical studies involving oral administration of SV. Both SV 
15 
 
and SVA were observed in the plasma samples. (Figure 5) Prueksaritanont et al. studied the complex 
metabolism of SV and SVA, which are both CYP3A4 substrates but also undergo interconversion in 
vivo. (Prueksaritanont et al., 2003) The pharmacokinetic parameters of both compounds are listed in 
Table 1. The Cmax of SVA (3.90 nM) is reached 140 min later than the Cmax of SV (23.3 nM). Similar Cmax 
and Tmax values were reported in literature. (Backman, 2000) The AUC0-8h of SV (36.10² nM.min) is 3.4 
times higher than the AUC0-8h of SVA (11.10² nM.min). Based on the AUC0-∞, the mean residence time 
(MRT) of SV was found to be 1.55 h.  
3.4.2. Gastrointestinal concentration-time profiles 
In parallel to the blood sampling, gastric and intestinal fluids were collected to investigate the 
intraluminal behavior of SV. Gastric and intestinal fluids were collected at predetermined time points 
and analyzed for the total amount per volume and concentrations of SV and SVA.  
3.4.2.1. Gastric concentration-time profiles 
Figure 6 shows the concentration-time profiles of SV and SVA in the stomach upon administration of 
one tablet of Zocor® (simvastatin, 40 mg). The concentrations (A) and total amount per liter (B) of SV 
and SVA are depicted. The pharmacokinetic parameters are shown in Table 2. The concentration-
time profiles of SV and SVA reach their Tmax value 44±15 min and 65±19 min, respectively, after drug 
administration, both reaching a Cmax of 3±3 µM. However, the total amount of SV and SVA per liter, 
are 75 and 19 times higher, respectively, than the concentration found in the stomach of both 
compounds. This finding is an in vivo confirmation of the poor dissolution and solubility 
characteristics that were observed for SV in gastric fluids in the dissolution study (Figure 2). 
Moreover, the two-stage dissolution test already predicted the concentrations of SV and SVA to be 
fairly similar in the stomach (Figure 4). These gastric concentrations reached in vivo remain 
somewhat lower than the maximum concentration that was measured during the performed 
dissolution study (Figure 2). (Rao et al., 2010) This can be explained by the continuous process of 
gastric emptying, keeping the concentrations of SV and SVA low. SVA exhibits a poor solubility (pKa 
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SVA = 4.21) in the low pH ranges of the aspirated gastric media. Based on the high Tmax value and the 
low concentrations of both SV and SVA, it can be concluded that SV dissolves slowly in the stomach, 
followed by conversion of SV to SVA. Subsequent precipitation of SVA results from its inferior 
solubility in gastric media as compared to SV.  
3.4.2.2. Intestinal concentration-time profiles 
Figure 7 depicts the duodenal concentration-time profiles of SV and SVA after the intake of one 
tablet of Zocor® (simvastatin, 40 mg); the concentrations (A) and the total duodenal amounts per 
liter (B) of SV and SVA are shown. The pharmacokinetic parameters, calculated based on the 
individual volunteers, are shown in Table 2. Both Cmax and AUC0-4h of the total amounts per liter of SV 
and SVA are lower in the intestine than in the stomach. In addition to the dilution that takes place 
upon transfer, this could also be caused by fast absorption of dissolved SV and SVA in the intestine. 
Both SV and SVA exhibit higher solubility in the intestine than in the acidic environment of the 
stomach, increasing the concentration gradient of SV and SVA across the intestinal layer, favoring the 
intestinal uptake of both compounds. The superior solubility and dissolution characteristics of SV in 
the intestinal fluids were evident from the in vitro dissolution experiments (Figure 2). Based on the 
obtained gastric and intestinal concentration-time profiles it can be concluded that dissolution of SV 
in the stomach is slow, followed by rapid conversion to the less soluble SVA, whereas in the intestine 
the superior dissolution rate, solubility and stability of SV leads to higher concentrations of 
solubilized SV. On the other hand, the concentrations of SVA at the level of the duodenum remain 
low as compared to the SV concentrations. This is probably due to the slow dissolution of SVA in 
intestinal fluids (Figure 2B) and the relatively good stability of SV in intestinal fluids (Figure 3B). Given 
the fact that intestinal absorption of SV (and SVA) is mostly dissolution limited, compound solubilized 
in the small intestine will be rapidly taken up across the intestinal barrier.  
When comparing the in vivo results with the results obtained during the two-stage dissolution 
experiments, similar findings were observed. SV slowly dissolves in FaHGF, but rapidly converts to 
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SVA. A fast degradation of SV to SVA was observed in the clinical study as well. (Table 2 and Figure 3) 
In the in vitro two-stage dissolution study using human intestinal fluids, concentrations of SV and SVA 
were similar as observed in the in vivo study. Moreover, the slow in vivo dissolution of SVA as 
compared to SV was also clearly reflected in the two-stage dissolution study. These findings 
underline the predictive and added value of this relatively simple in vitro experiment. Due to the 
simplicity and the good in vivo predictability of this in vitro experiment, it is warranted to explore the 
applicability of the two-stage dissolution tests for other API’s or formulations. 
Although, similar as in plasma, concentrations of SV in the small intestine are higher than those of 
SVA, it remains difficult to directly correlate the intestinal concentration profiles to the plasma 
profiles. Since no correlation could be found between the observed plasma and intraluminal 
concentrations, it can be assumed that the gut wall and hepatic metabolism have a major impact on 
the oral bioavailability of simvastatin and outweigh the importance of the intraluminal behavior of 
simvastatin. (Gertz et al., 2010) 
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4. CONCLUSION 
Based on the in vitro experiments, it could be concluded that (1) the dissolution of SV is slow; (2) the 
hydrolysis of SV to SVA occurs both in gastric and intestinal fluids while the lactone-hydroxyl acid 
interconversion was only observed in the gastric fluids and (3) the hydrolysis rate is higher in gastric 
fluids than in intestinal fluids, suggesting an important contribution of non-enzymatic hydrolysis to 
the overall intraluminal degradation of SV. By increasing the complexity of the in vitro set-ups, results 
more predictive for the in vivo situation were obtained. Despite the fact that, in case of SV, gut wall 
and hepatic metabolism outweigh the importance of the intraluminal behavior, the in vitro tools 
studied here can be useful to predict the gastrointestinal behavior of a prodrug.  
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5. FIGURE LEGENDS 
 
Figure 1: Metabolism of simvastatin in man. (adopted from(Pedersen and Tobert, 2004); 
(Prueksaritanont, 2002)) 
Figure 2: [A] Concentration-time profile of the dissolved amount of SV (●) and SVA (■) during the 
dissolution experiment in which 0.13 mg SV powder was added to 1 mL of FaHGF (175 rpm, 37 °C); 
[B] Concentration-time profile of the dissolved amount of SV (●) and SVA (■) during the dissolution 
experiment in which 0.13 mg of SV powder was added to 1 mL of FaHIF (175 rpm, 37°C). (Mean±SD, n 
= 3)) 
Figure 3: Stability of 10 µM SV (solid lines) in fasted state [A] gastric and [B] intestinal fluids in which 
SV degrades to SVA (dotted lines) after a period of time. (●) simulated gastric/intestinal fluids; (■) 
simulated intestinal fluids supplemented with 10 mg pancreatin per mL; (▲) human gastric and 
intestinal fluids in fasted state. (Mean±SD, n = 3) 
Figure 4: Concentration-time profile of SV (●) and SVA (■) during the two-stage dissolution testing. 
(A) The addition of one tablet of Zocor® (simvastatin, 40 mg) to simulated fluids and (B) the addition 
of 0.8 mg of SV to 1 mL of human fluids. (Mean±SD, n = 3) 
Figure 5: Plasma-concentration-time profile of SV (●) and SVA (■) in the fasted state condition after 
the administration of one tablet of Zocor® (simvastatin, 40 mg) to healthy volunteers. (Mean±SEM, n 
= 5) 
Figure 6: Concentration-time profile of SV (●) and SVA (■ ) in the stomach after the intake of one 
tablet of Zocor® (simvastatin, 40 mg) by healthy volunteers in the fasted state condition. (A) 
Concentration-time profile of the dissolved amount. (B) Concentration-time profile of the total 
amount. (Mean+SEM, n = 5) 
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Figure 7: Intestinal concentration-time profiles of SV (●) and SVA (■) after the intake of one tablet of 
Zocor® (simvastatin, 40 mg) by healthy volunteers in the fasted state condition. (A) Concentration-
time profile of the dissolved amount. (B) Concentration-time profile of the total amount. 
(Mean+SEM, n = 5) 
 
Table 1: The clinical pharmacokinetic parameters of SV and SVA in the fasted state after the 
administration of one tablet of Zocor® (simvastatin, 40 mg) to five healthy volunteers. (Median [min, 
max], n = 5) 
Table 2: The pharmacokinetic parameters, calculated based on the individual volunteers, of SV and 
SVA in both stomach and intestinal samples after the administration of one tablet of Zocor 
(simvastatin, 40 mg) to five healthy volunteers. (Mean±SD, n=5) 
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Table 1: 
 Simvastatin 
(SV) 
Simvastatin acid 
(SVA) 
C
max
 (nM) 23.3 [10.5-31.1] 3.90 [3.21-12.2] 
T
max 
(min) 99.6 [60.0-120] 240[210-300] 
AUC
0-8
 (nM.min) 3572 [663-6069] 11.10² [8.3.10²-27.10²] 
AUC 
0-∞
 (nM.min)a 3572 [663-6509] -
a 
Cl/F (L/h)  1698 [881-8646] -
 a 
MRT (h)  1.55 [0.83-2.12] -
 a 
Vdss (Cl/k)
  1868 [1627-7138] -
 a 
a Parameters could not be calculated due to an incorrect extrapolation of the AUC 
8-∞
.   
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Table 2: 
 Simvastatin (SV) Simvastatin acid 
(SVA) 
 Stomach Intestine Stomach Intestine 
C
max, dissolved
 
(µM) 
3.3±3.1 23±11 3.5±3.4 3.8±4.6 
T
max, dissolved 
(min) 
44±15 78±13 65±19 84±17 
AUC
0-4h, dissolved
 
(µM.min) 
270±150 1200±430 91±58 220±180 
C
max, total
 
(µmol/L) 
250±320 60±31 68±73 5.6±5.3 
T
max, total 
(min) 40±12 71±23 40±12 87±22 
AUC
0-4h, total
 
(µmol/L.min) 
9500±12000 2900±1500 2400±2500 320±240 
 
